The US Food and Drug Application (FDA) has agreed for priority review of a supplemental New Drug Application (sNDA) of AstraZeneca’s Lynparza (olaparib) as a maintenance treatment for ovarian cancer.
The sNDA seeks approval for newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer patients in complete or partial response after first-line standard platinum-based chemotherapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Being developed in alliance with Merck, Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor designed as a targeted therapy for DNA damage response (DDR) pathway deficiencies, such as BRCA mutations.
The drug holds approvals in more than 60 countries for platinum-sensitive relapsed ovarian cancer, irrespective of the BRCA status. It is also approved in certain markets to treat germline BRCAm HER2-negative metastatic breast cancer.
Lynparza sNDA for BRCA-mutated advanced ovarian cancer includes results from the pivotal Phase III SOLO-1 clinical trial performed to assess the drug’s efficacy and safety as maintenance monotherapy.
The randomised, double-blinded, placebo-controlled, multi-centre trial enrolled a total of 391 participants with a deleterious or suspected deleterious BRCA1 or BRCA2 mutation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAstraZeneca chief medical officer and Global Medicines Development executive vice-president Sean Bohen said: “The remarkable results of the SOLO-1 trial, which showed that 60% of women with newly diagnosed, advanced BRCA-mutated ovarian cancer remained progression-free at three years, highlight the potential of Lynparza as a maintenance therapy in the first-line setting.”
Primary endpoint of the trial was progression-free survival (PFS) and secondary endpoints included time to second disease progression or death, time to first subsequent treatment and overall survival.
Data revealed statistically-significant and clinically-meaningful improvement in PFS with Lynparza, compared to placebo. The drug is said to have minimised the risk of disease progression or death by 70%.
In the Lynparza arm, 60% of patients remained progression-free at 36 months, compared to 27% who received placebo.
Last month, the FDA granted orphan drug designation (ODD) for Lynparza (olaparib) to treat pancreatic cancer.
AstraZeneca and Merck partnered in July last year to co-develop and co-commercialise for a variety of cancer types.
